Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives $8.00 Consensus Target Price from Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has earned a consensus rating of “Hold” from the five brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $8.00.

A number of research analysts have recently commented on the stock. Wall Street Zen cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. HC Wainwright dropped their price objective on shares of Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Lake Street Capital cut their target price on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a report on Wednesday, October 8th. Finally, Zacks Research raised Sensus Healthcare from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 22nd.

Sensus Healthcare Stock Performance

Shares of SRTS stock opened at $4.11 on Friday. Sensus Healthcare has a fifty-two week low of $3.03 and a fifty-two week high of $9.30. The stock’s fifty day moving average price is $3.53 and its two-hundred day moving average price is $4.06. The company has a market cap of $67.51 million, a PE ratio of -68.50 and a beta of 1.38.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.06. The business had revenue of $6.88 million during the quarter, compared to the consensus estimate of $6.31 million. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%. On average, equities analysts predict that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Insider Transactions at Sensus Healthcare

In other news, Director Eric Sachetta purchased 7,000 shares of the business’s stock in a transaction dated Friday, November 21st. The shares were purchased at an average cost of $3.93 per share, with a total value of $27,510.00. Following the completion of the purchase, the director owned 140,113 shares of the company’s stock, valued at $550,644.09. This trade represents a 5.26% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Joseph C. Sardano acquired 25,000 shares of the stock in a transaction dated Tuesday, November 18th. The stock was purchased at an average cost of $4.03 per share, with a total value of $100,750.00. Following the purchase, the chief executive officer directly owned 1,200,293 shares of the company’s stock, valued at $4,837,180.79. This trade represents a 2.13% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 36,500 shares of company stock worth $147,570 over the last three months. Insiders own 8.90% of the company’s stock.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds have recently modified their holdings of the business. Kingstone Capital Partners Texas LLC acquired a new stake in Sensus Healthcare in the second quarter valued at $3,170,000. Divisadero Street Capital Management LP lifted its holdings in Sensus Healthcare by 459.4% during the 2nd quarter. Divisadero Street Capital Management LP now owns 324,673 shares of the company’s stock worth $1,539,000 after buying an additional 266,635 shares during the period. Acadian Asset Management LLC increased its stake in shares of Sensus Healthcare by 35.3% in the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock valued at $2,225,000 after buying an additional 122,746 shares during the period. Pacific Ridge Capital Partners LLC raised its position in shares of Sensus Healthcare by 26.1% during the third quarter. Pacific Ridge Capital Partners LLC now owns 573,389 shares of the company’s stock worth $1,800,000 after acquiring an additional 118,628 shares during the last quarter. Finally, Meros Investment Management LP bought a new position in shares of Sensus Healthcare during the first quarter worth about $419,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.